Antiphospholipid Antibody Syndrome
8
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
85.7%
-0.8% vs benchmark
13%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
Rivaroxaban for Antiphospholipid Antibody Syndrome
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome